Lv6
1810 积分 2025-01-05 加入
LBA72 NorthStar: A phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC)
4小时前
求助中
LBA72 NorthStar: A phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC)
4小时前
已关闭
Lung cancer biomarkers: Raising the clinical value of the classical and the new ones
2个月前
已完结
Thoracic radiotherapy PLUS durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy: Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy—The TRADE-hypo trial
2个月前
已关闭
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
2个月前
已完结
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer – The ETOP 19-21 USZ-STRIKE study
2个月前
已完结
Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer
2个月前
已完结
Amivantamab: First Approval
2个月前
已完结
Study Highlights Difficulties in the Diagnosis of Myelodysplastic Neoplasms (MDS)
皖公网安备34019202002308
